Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Two India Firms In Fresh FDA Trouble: Emcure Hit By Warning Letter, Dr Reddy’s Gets 483

Executive Summary

The US regulator has slammed India’s Emcure Pharmaceuticals in a warning letter, accusing the company of slipshod investigation of tests showing microbial contamination and poor supervision, and has also sent a Form 483 containing eight observations to Dr Reddy’s.

You may also be interested in...



Emcure Aims To Split Itself In Half

By the middle of next year, Emcure intends to have demerged its operations in highly developed markets from its activities in India and other emerging markets. The Indian group is seeking private-equity support to grow inorganically in North America and Europe.

The Next New Thing In FDA Inspections: Poor Root Cause Investigations

Data integrity failures are so yesterday. Now it’s all about poor investigations into out-of-specification results.

Generic Price-Fixing Lawsuit Grows As More Companies, Two Executives Named Defendants

US state attorneys general name executives from Mylan and Emcure as defendants, and list may further expand as investigation continues into additional companies and drugs.

Topics

Related Companies

UsernamePublicRestriction

Register

GB149106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel